Anti-tuberculosis activity of morusin: a promising flavonoid from white mulberry.

IF 3.4 3区 医学 Q2 INFECTIOUS DISEASES International Journal of Tuberculosis and Lung Disease Pub Date : 2024-01-01 DOI:10.5588/ijtld.23.0224
K Yildirim, S Bozkurt, H H Basibuyuk, A Y Coban
{"title":"Anti-tuberculosis activity of morusin: a promising flavonoid from white mulberry.","authors":"K Yildirim, S Bozkurt, H H Basibuyuk, A Y Coban","doi":"10.5588/ijtld.23.0224","DOIUrl":null,"url":null,"abstract":"<p><p><b>BACKGROUND:</b> TB has remained a significant public health concern from historical times to the present day. Each year, growing drug resistance problems necessitate the discovery of new drugs and drug precursors for TB treatment. Morusin is an important flavone found in the bark of white mulberry (<i>Morus alba</i> L.) with anti-oxidant, antimicrobial, anti-tumour, anti-inflammatory and antiallergic activity.<b>OBJECTIVE:</b> To determine the anti-TB efficacy of morusin on <i>Mycobacterium tuberculosis</i> strains.<b>DESIGN:</b> Anti-TB efficacy of morusin was tested on H37Ra (American Type Culture Collection [ATCC] 25177), H37Rv (ATCC 27294), ATCC 35822 (isoniazid [INH] resistant), ATCC 35838 (rifampicin [RIF] resistant), and ATCC 35820 (streptomycin [SM] resistant) standard strains and its efficacy was determined using nitrate reductase assay (NRA).<b>RESULTS:</b> The minimum inhibitory concentration (MIC) of morusin was tested in the range of 53.83â-\"0.21 μg/ml. The MIC for H37Ra (ATCC 25177), H37Rv (ATCC 27294) and ATCC 35838 (RIF-resistant) strains were found to be 6.72 μg/ml, and this was 13.45 μg/ml for the ATCC 35822 (INHresistant) and ATCC 35820 (SM-resistant) strains.<b>CONCLUSION:</b> To consider morusin as a viable alternative or precursor drug for TB treatment, it is imperative to conduct an exhaustive examination of its mechanism of action and conduct in vitro studies using clinical isolates.</p>","PeriodicalId":14411,"journal":{"name":"International Journal of Tuberculosis and Lung Disease","volume":null,"pages":null},"PeriodicalIF":3.4000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Tuberculosis and Lung Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5588/ijtld.23.0224","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

BACKGROUND: TB has remained a significant public health concern from historical times to the present day. Each year, growing drug resistance problems necessitate the discovery of new drugs and drug precursors for TB treatment. Morusin is an important flavone found in the bark of white mulberry (Morus alba L.) with anti-oxidant, antimicrobial, anti-tumour, anti-inflammatory and antiallergic activity.OBJECTIVE: To determine the anti-TB efficacy of morusin on Mycobacterium tuberculosis strains.DESIGN: Anti-TB efficacy of morusin was tested on H37Ra (American Type Culture Collection [ATCC] 25177), H37Rv (ATCC 27294), ATCC 35822 (isoniazid [INH] resistant), ATCC 35838 (rifampicin [RIF] resistant), and ATCC 35820 (streptomycin [SM] resistant) standard strains and its efficacy was determined using nitrate reductase assay (NRA).RESULTS: The minimum inhibitory concentration (MIC) of morusin was tested in the range of 53.83â-"0.21 μg/ml. The MIC for H37Ra (ATCC 25177), H37Rv (ATCC 27294) and ATCC 35838 (RIF-resistant) strains were found to be 6.72 μg/ml, and this was 13.45 μg/ml for the ATCC 35822 (INHresistant) and ATCC 35820 (SM-resistant) strains.CONCLUSION: To consider morusin as a viable alternative or precursor drug for TB treatment, it is imperative to conduct an exhaustive examination of its mechanism of action and conduct in vitro studies using clinical isolates.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
morusin的抗结核活性:白桑中一种有前途的黄酮类化合物。
背景:从古至今,结核病一直是一个重大的公共卫生问题。每年,由于耐药性问题日益严重,因此有必要发现治疗结核病的新药物和药物前体。Morusin 是白桑树(Morus alba L.)树皮中发现的一种重要黄酮,具有抗氧化、抗菌、抗肿瘤、抗炎和抗过敏活性。设计:在 H37Ra(美国类型培养物保藏中心 [ATCC] 25177)、H37Rv(ATCC 27294)、ATCC 35822(耐异烟肼 [INH])、ATCC 35838(耐利福平 [RIF])和 ATCC 35820(耐链霉素 [SM])标准菌株上测试吗菌素的抗结核功效,并使用硝酸还原酶测定法(NRA)确定其功效。结果:莫鲁信的最低抑菌浓度(MIC)为 53.83-"0.21 δg/ml。H37Ra(ATCC 25177)、H37Rv(ATCC 27294)和ATCC 35838(RIF耐药)菌株的MIC为6.72 μg/ml,ATCC 35822(INH耐药)和ATCC 35820(SM耐药)菌株的MIC为13.45 μg/ml。结论:要将吗丁啉视为治疗结核病的可行替代药物或先导药物,必须对其作用机制进行详尽研究,并利用临床分离菌株进行体外研究。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.90
自引率
20.00%
发文量
266
审稿时长
2 months
期刊介绍: The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.
期刊最新文献
Building social equity and person-centred innovation into the end TB response. Cascade of care for TB infection in persons newly diagnosed with HIV in Italy. Clinical characteristics and decortication outcomes of bacterial, tuberculous and fungal pleural infection. Impact of hyponatraemia during exacerbation on clinical outcomes in patients with bronchiectasis. Omadacycline enhances the in vitro activity of clofazimine against Mycobacterium abscessus.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1